What happened
Paradigm Peptides ceased operations in December 2025 following a
federal plea entered in U.S. district court. The formal charges
concerned SARMs labeled products that contained testosterone —
testosterone is a Schedule III controlled substance under
21 U.S.C. § 802(41), and selling it without a license to do so is the
underlying federal offense.
The peptide catalog was not the formal subject of the action. The
charging documents reference the SARMs-with-testosterone products
specifically. But the operation closed in its entirety as part of the
plea resolution: the vendor's website went offline, the peptide
catalog along with the SARMs catalog stopped shipping, and the
customer-service channels stopped responding.
What we read
For this postmortem we synthesized: the publicly-available DOJ press
release accompanying the December 2025 plea; the federal court filings
from the Eastern District of (court detail withheld pending full
unsealing) referenced in contemporaneous trade reporting; r/Peptides
community threads from the 90 days preceding the plea; and the
Peptide Catalog post-shutdown coverage.
This is a forensic public-data piece, not a first-hand audit.
The pattern, again
Paradigm Peptides is the second of three top-tier US peptide vendors
to close in the 2025–2026 cycle, all under structurally similar
circumstances. The pattern across all three:
| Vendor | Closed | Formal cause |
|---|---|---|
| Amino Asylum | Jun 2025 | Federal raid; SARMs products containing testosterone |
| Paradigm Peptides | Dec 2025 | Federal plea; SARMs products containing testosterone |
| Peptide Sciences | Mar 2026 | Quality collapse + federal pressure |
The first two cases share the same structural feature: the formal
cause of action was not the peptide catalog. It was the
controlled-substance handling on a parallel SARMs product line. The
peptide catalog ceased operating because the operation it sat inside
ceased operating.
This matters for the buyer because it means the public quality data
on the peptide catalog (COAs, shipping reliability, customer service)
is not predictive of operational continuity. A vendor can be
running a clean peptide catalog and still close because of unrelated
catalog decisions. Reading the COA is necessary but not sufficient.
Pre-shutdown signals that were visible
The Paradigm Peptides case had a longer public-record runway than the
Amino Asylum case. The investigation reportedly began in mid-2024
based on charging-document references to evidence-collection dates.
The 18-month window between investigation start and plea is long
enough that the buyer-side public signals were visible.
What was visible in 2024–2025:
- DOJ press releases in March 2025 announcing an expansion of the
SARMs-with-testosterone investigation track (no vendors named in
the announcement, but the policy direction was public)
- Trade-press reporting through summer 2025 referencing
"additional federal actions expected" against research-chemical
vendors
- Community speculation on r/Peptides through autumn 2025 noting
Paradigm's catalog changes (some SKUs removed, others repriced) —
often a sign of legal counsel guidance during a pending case
None of these signals were proof of imminent shutdown. Each was a
risk indicator. A buyer who was tracking the
FDA Warning Letters database
and DOJ press releases over 2024–2025 would have had Paradigm on a
risk list well before the December plea.
Where the catalog migrated
Following the December 2025 plea, Paradigm Peptides customers
migrated similarly to the post-Amino-Asylum migration pattern, with
some specific differences:
- Ascension Peptides absorbed a portion of the GLP-1 customer base
(see our Ascension Peptides preview profile)
- Pure Rawz absorbed a portion of the catalog-breadth seekers
(see our Pure Rawz preview profile)
- A portion of the customer base migrated to non-US-domestic vendors
(Swiss Chems and similar) following the second top-tier US closure
in six months
The pattern was not uniform. Paradigm's customer base was more
catalog-breadth-driven than Amino Asylum's (which was more
price-driven), and the migration tracked accordingly.
Lessons for the buyer
Watch for parallel-product-line risk. A vendor running a clean
peptide catalog alongside a less-clean SARMs or research-chemical
line carries risk that the peptide-catalog COAs do not capture. The
two top-tier US shutdowns of 2025 both involved this pattern.
Public investigation signals run on long timelines. The Paradigm
case had an 18-month investigation runway. The buyer who tracked DOJ
press releases and FDA Warning Letters had time to migrate before the
plea. The buyer who only tracked vendor-side signals (COAs, prices,
shipping speeds) did not.
Migrations cluster by vendor positioning. Customers don't migrate
randomly after a closure; they migrate to the closest catalog-and-pricing
match. Knowing the positioning of vendors in the cycle helps predict
where displaced demand goes — which is also where the next quality
risk concentrates.
Sources